Patent: 10,124,038

Summary for Patent: 10,124,038

Title:	Modulators of syndecan-2 and uses thereof
Abstract:	Modulators of syndecan-2, such as an antibody to syndecan-2 that cross-links syndecan-2 on the cell surface or a syndecan-2 polypeptide that interferes with syndecan-2 receptor binding, is used to regulate a Th17 mediated disease such as an autoimmune disease, fibrosis or cancer.
Inventor(s):	Elliman; Stephen J. (Galway, IE), Barkley; Laura Rose (Galway, IE), Kavanaugh; Jack (Los Angeles, CA)
Assignee:	ORBSEN THERAPEUTICS LIMITED (Galway, IE)
Application Number:	15/074,681
Patent Claims:	see list of patent claims

United States Patent 10,124,038: What Do the Claims Actually Cover, and Where Are the Crowded Patent Areas?

US 10,124,038 is drafted as a method-of-treatment and composition package built around (i) identifying a patient with an autoimmune/fibrotic/cancer indication and (ii) administering an “inhibitor of Th17 cell activity” that is defined structurally: a polypeptide with (a) a first region taken from SEQ ID NO: 4-13 and (b) a second region comprising a dimerization domain (claim 12 specifies the dimerization domain as an Fc domain). The claims also layer extensive option sets: immune effector cell types (TIL, stem central memory T, CAR-T, TCR-T, NK) and co-therapies spanning NSAIDs, TNFα inhibitors, standard fibrosis drugs, and a long oncology agent roster.

At the core, the patent’s enforceability depends on whether the “Th17 inhibitor” polypeptide definition is sufficiently narrow to avoid prior art Th17 antagonists and whether the SEQ ID NO: 4-13 region plus Fc-dimerized format is distinguishable over earlier engineered Fc fusion/dimerization protein disclosures targeting IL-17/Th17 pathways.

---

What Is Claimed, in Claim-Layer Form?

Claim 1: The structural Th17 inhibitor and the treatment decision

Claim 1 recites a method for treating at least one disorder selected from:

• autoimmune disorder
• fibrotic disorder
• cancer

The method includes:

1. identifying a subject needing treatment for at least one disorder from the list; and
2. administering a “dosage regimen of an inhibitor of Th17 cell activity” comprising a polypeptide with:
   • first region selected from polypeptides corresponding to SEQ ID NO: 4-13
   • second region comprising a dimerization domain

Key claim construction points

• The Th17 inhibitor is not defined by mechanism alone; it is defined by a polypeptide architecture (SEQ ID 4-13 region + dimerization domain).
• The method is broad on indication but narrows the active ingredient definition structurally.
• The dosage regimen is mentioned in claim 1 but the only explicit dose range appears in claim 2.

Claim 2: Dose band

Claim 2 specifies administration at about 0.1 mg to 2 mg per administration.

Claims 3-5: Cell-type add-on for autoimmune and cancer

• Claim 3: for autoimmune disorders, the method comprises administering at least one T cell.
• Claim 5: for cancer, the method comprises administering at least one anti-cancer cell selected from:
  • TIL
  • stem central memory T cell
  • CAR-T
  • TCR-T
  • NK

Claims 4, 6, 7, 9: Broad co-therapy lists

• Claim 4 (autoimmune co-therapy): includes NSAIDs and a long list of immune-modulating agents such as:
  • NSAIDs including ibuprofen, naproxen, celecoxib, etoricoxib, etc.
  • DMARDs and biologics such as methotrexate, hydroxychloroquine, sulfasalazine, leflunomide
  • TNFα inhibitors and others including etanercept, adalimumab, infliximab, certolizumab pegol, golimumab
  • abatacept, rituximab, tocilizumab, anakinra, cyclosporine, antithymocyte globulin, mycophenolate mofetil, cyclophosphamide
• Claim 6 (cancer co-therapy): includes a very broad oncology agent roster spanning classic chemo, targeted agents, and biologics including cisplatin, paclitaxel, gemcitabine, doxorubicin, cetuximab, bendamustine, dasatinib, lenalidomide, etc.
• Claim 7 (fibrosis co-therapy): includes nintedanib, pirfenidone, corticosteroid, and beta-agonists (albuterol, levabuterol, salmeterol, formoterol).
• Claim 9 (autoimmune co-therapy): includes an NSAID and a TNFα inhibitor.

Claim 8: A stromal stem cell population marker requirement

Claim 8 adds a stromal stem cell population comprising stem cells at least 30% syndecan-2 positive.

Claims 10-12: Composition claims with buffer and Fc dimerization

• Claim 10: an isolated composition comprising:
  • the polypeptide fragment in solution having:
    • first region = polypeptide selected from SEQ ID NO: 4-13
    • second region = dimerization domain
  • at least one living immune effector cell
  • buffer suitable for intravenous administration
• Claim 11: immune effector cell types include TIL, stem central memory T, CAR-T, TCR-T, NK.
• Claim 12: dimerization domain comprises an Fc domain.

---

Where the Patent Likely Sits in the Landscape: Crowding vs. Novelty

The “Fc-dimerized Th17 inhibitor polypeptide” is the likely battleground

The enforceability profile hinges on whether US 10,124,038’s “inhibitor of Th17 cell activity” polypeptide is an engineered construct that is:

• novel in sequence (SEQ ID NO: 4-13),
• novel in architecture (SEQ region plus Fc-dimerization), and/or
• novel in combination usage (dose + co-therapies + immune effector cells).

If earlier art already teaches Fc-fusion or Fc-dimerized proteins with functional Th17/IL-17 pathway inhibition, then the combination with SEQ ID 4-13 may be the only meaningful differentiator.

The indication breadth increases invalidity exposure

The claims cover:

• autoimmune,
• fibrosis,
• cancer,

and then layer extensive co-therapy lists. That breadth invites prior art combinations unless the Th17 inhibitor construct itself drives novelty.

Practically, examiners and litigators will likely treat the Th17 inhibitor definition as the sole “hard” limitation, with the rest read as conventional add-on categories unless tightly integrated.

The immune effector/cell option set is broad enough to be saturated

CAR-T, TCR-T, NK, and TIL are well-known categories in oncology. Their presence in claims as optional cell types increases the chance the oncology portion is not the novel contribution. The novelty, if any, is more likely tied to the Th17 inhibitor.

---

Claim-by-Claim Critical Analysis: Strengths and Weak Points

1) Is claim 1 narrow enough to survive prior art?

Strong aspects

• The active ingredient is structurally defined (SEQ ID 4-13 + dimerization domain).
• Dimerization domain plus a specific set of SEQ ID-derived first regions can limit the scope.

Weak aspects

• Claim 1 does not explicitly require Fc; Fc is only in claim 12.
• “Inhibitor of Th17 cell activity” is functional at the claim level and could be argued as met by earlier IL-17/Th17 pathway blocking agents even if architecture differs, depending on how the SEQ region is mapped to prior sequences.
• The method applies to three large disease categories, which can pull in broad prior art.

2) Dose range in claim 2 can be both help and risk

Potential help

• A bounded dose range can distinguish from prior art where the construct is dosed differently.

Potential risk

• A range of 0.1 mg to 2 mg may be attacked as obvious or overlapping with typical dosing bands for Fc fusion proteins or biologics.

3) Claims 3 and 5: T-cell and anti-cancer cell types

These claims are likely non-distinguishing unless the specification ties these cell populations to a specific functional synergy with the Th17 inhibitor.

• Claim 5’s list includes the major adoptive cell therapies and NK cells, which are widely known.
• Claim 3’s “at least one T cell” is extremely broad and likely reads onto routine T-cell administrations already in the record.

4) Co-therapy lists in claims 4, 6, and 9: breadth weakens patentability

• Claim 4 includes NSAIDs and a sweeping roster of autoimmune agents and biologics, including TNFα inhibitors.
• Claim 6 lists a long roster of chemotherapies, targeted therapies, and supportive oncology agents.

Such lists raise obviousness risk because they look like “any standard co-therapy” rather than a tightly linked combination to Th17 biology.

5) Fibrosis claim 7: standard-of-care list

nintedanib and pirfenidone are core fibrosis drugs. Adding beta-agonists and corticosteroids further normalizes the fibrosis regimen.

If US 10,124,038’s novelty is the Th17 inhibitor, claim 7’s co-therapy list does little for distinctiveness.

6) Claim 8’s syndecan-2 positive stem cell threshold is a potential anchor

This is a more specific biological marker condition:

• at least 30% syndecan-2 positive stem cells.

If earlier art lacks this exact biomarker threshold in a compatible therapeutic context, claim 8 may be the most defensible “extra limitation” beyond the Th17 inhibitor.

7) Composition claims 10-12: Fc-dimerization specificity matters

Claim 10 captures a composition with:

• the SEQ ID 4-13 polypeptide fragment,
• dimerization domain,
• living immune effector cells,
• IV-suitable buffer.

Claim 12 narrows the dimerization domain to an Fc domain.

From an infringement standpoint, claim 12 creates a direct tie to Fc-fusion format. From a validity standpoint, Fc fusion Th17/IL-17 pathway inhibitors are a known design theme, so novelty rests again on the SEQ ID region and how it maps to earlier sequences.

---

Enforcement Outlook: Likely Claim Targets vs. Likely Design-Arounds

Likely claim targets

• The patents’ enforceable hook is the specific structural definition of the Th17 inhibitor:
  • first region in the set of SEQ ID NO: 4-13
  • second region = dimerization domain (and potentially Fc per claim 12)

Thus, a product that uses a different dimerization architecture or different first-region sequences can avoid literal infringement, depending on claim construction.

Likely design-arounds

• Change the dimerization domain away from Fc (avoid claim 12 literal coverage; attack claim 1 scope by arguing “dimerization domain” is not met or architecture differs).
• Use the same biological concept (Th17 inhibition) but with a different first region sequence that does not fall inside SEQ ID NO: 4-13.
• Avoid the living immune effector cell requirement if targeting method claims only, or avoid the composition requirements if targeting administration routes that do not match the “IV composition” structure.

Where “broad co-therapy lists” may not help enforcement

Even if a competitor uses the Th17 inhibitor architecture, their non-use of specific co-therapies may still leave method claims at risk depending on interpretation of whether “comprising administering at least one” requires the co-therapy in every instance.

Because claims 4, 6, 7, and 9 specify optional co-therapy add-ons as “wherein” clauses, they likely function as narrower dependent claims that competitors can avoid.

---

Patent Landscape Read: What to Expect in Prosecution and Litigation

High-level categories likely to exist around this space

Given the claim language, US 10,124,038 overlaps conceptually with:

• engineered IL-17/Th17 pathway inhibitors,
• Fc-fusion protein formats,
• engineered immunomodulatory polypeptides with dimerization,
• adoptive immune cell therapy regimens for oncology combined with immunomodulators,
• autoimmune and fibrotic treatment frameworks using NSAIDs/DMARDs and approved fibrosis agents.

In practice, the landscape will be crowded at three layers:

1. Th17/IL-17 inhibitors (functional claim theme).
2. Fc-dimerized protein engineering (structural theme).
3. combination therapy frameworks using conventional agents and cell therapies (indication/usage theme).

The only likely differentiator is the exact SEQ ID NO: 4-13 region content and how it is tied to Th17 inhibition.

---

Key Takeaways

• US 10,124,038 is structurally anchored on a Th17 inhibitor polypeptide defined by SEQ ID NO: 4-13 plus a dimerization domain, with Fc explicitly required in claim 12.
• Most other claim elements are option lists (oncology drugs, NSAIDs/DMARDs/TNFα inhibitors, immune effector cell categories), which increases obviousness and reduces distinctiveness unless the specification tightly ties them to the Th17 inhibitor mechanism.
• Claim 12 (Fc dimerization) is the strongest structural limiter for infringement analysis, while claim 8 (≥30% syndecan-2 positive stem cells) is a notable biological limitation that can improve defensibility.
• The enforceability outcome will primarily turn on whether the SEQ ID 4-13 region plus Fc-dimerized format is novel over prior Fc-engineered immunomodulators affecting Th17/IL-17 pathways.

---

FAQs

1) What is the single most important limitation in US 10,124,038?
The most important is the Th17 inhibitor polypeptide architecture: first region from SEQ ID NO: 4-13 plus a dimerization domain (with Fc specified in claim 12).

2) Does the patent claim a specific Th17 target (like IL-17A/F) by name?
The provided claim text uses functional language (“inhibitor of Th17 cell activity”) and does not require a named cytokine target in the claims as quoted.

3) Are the autoimmune and oncology co-therapy lists likely to confer strong patentability?
They are broad and read like standard regimen components, which typically weakens their distinctiveness unless the specification ties them to a unique, claimed synergy.

4) Which dependent claim adds the most specific biological condition beyond polypeptide structure?
Claim 8, requiring a stromal stem cell population with at least 30% syndecan-2 positive stem cells.

5) Where is the best infringement leverage for a party asserting the patent?
Against products that use the SEQ ID NO: 4-13-based polypeptide and especially those using an Fc dimerization domain as in claim 12.

---

References

[1] US Patent 10,124,038, “Method of treating autoimmune disorder, fibrotic disorder and cancer using Th17 inhibitor polypeptide,” claims provided in user prompt.

Details for Patent 10,124,038

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	November 26, 1997	10,124,038	2036-03-18
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	August 24, 1998	10,124,038	2036-03-18
Immunex Corporation	ENBREL	etanercept	For Injection	103795	November 02, 1998	10,124,038	2036-03-18
Immunex Corporation	ENBREL	etanercept	For Injection	103795	May 27, 1999	10,124,038	2036-03-18